Osteogenesis imperfecta (OI), often called brittle bone disease, affects roughly 1 in 15,000 to 20,000 births worldwide, making it one of the more common heritable skeletal disorders even though it remains classified as rare. The condition spans an enormous clinical spectrum, from people who fracture a handful of times across their lives to infants who die in the womb or shortly after birth. That range maps loosely onto a classification system of numbered types, though the genetics behind OI have turned out to be far more complicated than the original four-type scheme suggested.
The Four Classical Types and Their Relative Frequency
The classification most clinicians still rely on was introduced by David Sillence and colleagues in the late 1970s, grouping OI into four types based on clinical severity, radiological findings, and inheritance patterns. Since then, genetic discoveries have expanded the list considerably, but the original four types still account for the vast majority of diagnosed cases.
Type I is the mildest and most common form. People with Type I typically produce about half the normal amount of type I collagen, the main structural protein in bone, because one copy of the gene responsible is essentially silenced. Fractures happen but are far fewer than in more severe forms. In a study of Kazakhstani children, patients with Type I reported a median of six lifetime fractures, and their bone quality allowed most to lead active lives.
Type II is the most severe form and is almost always lethal around the time of birth. The mutations responsible usually involve dominant changes in the COL1A1 or COL1A2 genes, affecting roughly 80 to 90 percent of cases. Most Type II cases arise from brand-new (de novo) mutations rather than inheritance from a parent, although recurrence within families does happen. In one study of 65 families, about 8.6 percent of siblings were also affected, a pattern partly explained by one parent carrying the mutation in a fraction of their reproductive cells without showing symptoms themselves.
Type III is the most severe form compatible with survival past infancy. These individuals accumulate the highest number of fractures over their lifetimes. In the Kazakhstani cohort, patients with Type III had a median of 20 fractures, compared with five or six for Types I and IV. Progressive skeletal deformity, very short stature, and significant disability are common.
Type IV falls between Types I and III in severity. It tends to be moderate, with fractures starting somewhat later in life. In the same Kazakhstani study, patients with Type IV had the highest median age at first fracture, around three years, suggesting a milder disease course compared to Type III.
How Classification Has Evolved
The Sillence system was built in an era when the molecular basis of OI was still unclear. As researchers identified more genes, the classification expanded to include Types V through at least XV, depending on which system you follow. This expansion has created some confusion, because some specialists prefer numbering each new genetic cause as a distinct type, while others group them by clinical severity regardless of the gene involved.
In 2010 and again in later revisions, the International Nosology of Skeletal Dysplasias moved toward a framework that recognizes phenotypic overlap across genetic causes. The successive revisions highlight a tension in the field: clinicians need categories that predict how severe a patient’s disease will be, while geneticists want categories that reflect which molecular pathway is disrupted.
The practical consequence for patients and families is that the same “type” label can mean slightly different things depending on who assigned it and when. A clinician may call a moderate case “Type IV” based on appearance, while genetic testing reveals a mutation more commonly associated with a different numbered type. This is why genetic testing has become increasingly central to diagnosis and prognosis.
Rarer Types and the Genes Behind Them
Beyond the classical four, the rarer forms of OI are caused by mutations in genes that interact with collagen processing rather than coding for collagen itself. These include genes like LEPRE1, CRTAP, SERPINF1, IFITM5, FKBP10, WNT1, and others. Mutations in LEPRE1 and CRTAP, which encode proteins involved in a collagen-modifying enzyme complex, cause autosomal recessive OI that can be clinically indistinguishable from Types II or III.
Type V OI stands out because it is caused by a specific mutation in the IFITM5 gene and produces distinctive features not seen in collagen-based OI, including overgrowth of callus tissue at fracture sites and calcification of the membrane between the forearm bones. In one Ukrainian and Vietnamese cohort, Type V accounted for about 1.5 percent of all OI patients. A larger study following 29 patients with rare OI types found that IFITM5 mutations were the most common cause among them, accounting for roughly 62 percent of the rare-type group, while mutations in LEPRE1, SEC24D, and SERPINF1 each made up about 7 percent.
Dominant Versus Recessive Inheritance
The genetics of OI are dominated by one fact: over 90 percent of affected people carry a mutation in one of the two type I collagen genes, COL1A1 or COL1A2, and these mutations follow autosomal dominant inheritance. That means a single altered copy of the gene is enough to cause disease. In a large Chinese cohort, about 38 percent of patients with collagen gene mutations had de novo variants, meaning neither parent carried the mutation in their blood cells. The remaining 62 percent inherited the mutation from a parent.
The recessive forms, caused by mutations in the collagen-processing genes mentioned above, are individually very rare but collectively important, especially in populations with high rates of consanguinity (marriage between relatives). In these communities, carrier parents each pass on one copy of a recessive mutation, and children who receive both copies develop the disease. Recessive OI tends to be moderate to severe, and its clinical appearance often overlaps with the severe dominant forms, making genetic testing essential for accurate diagnosis.
Population-Specific Prevalence Patterns
Although OI occurs in every ethnic group, certain founder mutations make the disease more common in specific populations. A striking example involves a LEPRE1 mutation found in West African and African American communities. About 1.5 percent of unrelated individuals in Nigeria and Ghana carry this mutation, predicting that roughly 1 in 18,260 births in those regions will have recessive OI, a rate equal to the incidence of new dominant OI mutations in the general population. Among Mid-Atlantic African Americans, the carrier rate drops to about 0.4 percent, estimating recessive OI in roughly 1 in 260,000 births. Genetic analysis suggests this mutation arose from a single founder between 1100 and 1350 CE.
A similar founder effect has been documented in Chinese populations, where a specific PPIB mutation causing OI Type IX appears unique to individuals from mainland China and Taiwan. The mutation shares a common ancestral haplotype across all identified carriers, consistent with descent from a single historical founder. These population-specific clusters matter because they influence genetic counseling and carrier screening strategies in affected communities.
Fracture Patterns Across the Lifespan
The hallmark of OI is fracture susceptibility, but fracture rates are not constant across a person’s life. In a large study of over 6,400 individuals, fracture rates were highest during childhood and lowest in early adulthood for both sexes. This pattern makes intuitive sense: childhood involves rapid growth and active play, while young adults have reached peak bone mass and tend to be more careful.
The picture shifts again with aging. Women with milder OI saw fracture rates climb after age 51, coinciding with menopause and the drop in estrogen that accelerates bone loss in all women. Men with milder OI had relatively stable fracture rates as they aged, though men with severe OI also experienced increases in later life. A systematic review of the natural history of OI confirmed that limb fractures are the most commonly reported throughout life, while hip, spine, and femur fractures become more prominent with aging, pregnancy, and menopause.
This lifelong fracture trajectory means that people with OI need bone-health monitoring well beyond childhood. The disease is sometimes framed as a pediatric condition, but the adult burden is substantial and ongoing.
Beyond Broken Bones
OI is not just a bone disease. Because type I collagen is found throughout the body, the effects reach well beyond the skeleton. Hearing loss is one of the most common extraskeletal features, with prevalence rates ranging from 50 to 92 percent depending on the study and the type of OI examined. The hearing loss typically involves the middle ear bones, which are themselves made of collagen-rich tissue, though inner ear damage can also contribute. Many people with OI develop hearing problems starting in their twenties or thirties, and the loss tends to be progressive.
Other common features include blue or gray discoloration of the whites of the eyes (blue sclerae), dental problems from poorly formed dentin (dentinogenesis imperfecta), increased joint flexibility, and short stature, especially in the more severe types. The blue sclerae are most pronounced in Type I and result from the sclera being thin enough for the underlying tissue to show through. Dental involvement varies widely and can require extensive restorative work starting in childhood.
Mobility and Quality of Life by Type
How independently someone with OI can move depends heavily on which type they have. A multicenter North American study measured walking ability across OI types and found stark differences. People with Type I scored highest on walking-ability scales, with an average score of 9.6 out of 10, and most could walk independently on all surfaces. Those with Type IV averaged 6.7, while people with Type III averaged 4.1 and typically needed a wheelchair or walker, especially for longer distances.
When tested on a six-minute walk, individuals with Type I covered distances about 30 percent shorter than healthy adults, while those with Type III who could complete the test walked 62 percent less than expected. These gaps reflect not just bone fragility but also the cumulative effects of deformity, muscle weakness, and joint laxity on functional capacity.
A systematic review of quality-of-life studies in adults with OI found that people with Type III reported lower physical and respiratory quality of life compared to those with Type I, which is expected given the severity difference. Mental health quality of life, however, was largely preserved across types. This finding suggests that many adults with OI adapt psychologically to their condition, even when physical limitations are severe.
Prognosis and Causes of Death
Survival in OI varies dramatically by type. People with Types I and IV often have normal or near-normal lifespans and frequently die of causes unrelated to their bone disease, such as heart attack or cancer. For those with Type III, the picture is different. The progressive spinal curvature (kyphoscoliosis) that develops in severe OI compresses the chest, reducing lung capacity and eventually leading to respiratory failure or heart failure. A study examining causes of death in OI found that respiratory deaths and cardiac failure from chest deformity were significant contributors in Type III, while many deaths in Types I and IV were clearly unrelated to OI.
Type II remains lethal at or around birth in nearly all cases. The bones are so fragile that the rib cage cannot support breathing, and skull fractures or other injuries during delivery or the perinatal period are common.
When OI Gets Mistaken for Child Abuse
One of the most consequential diagnostic pitfalls involves mild or moderate OI being confused with non-accidental injury in young children. Both can present with multiple fractures that lack an obvious explanation. Case reports document children being removed from their families and parents being investigated for abuse before the underlying diagnosis of OI was recognized. A case report described a 20-month-old girl with four fractures between three and eighteen months of age who was initially flagged for suspected child abuse before OI was identified.
The overlap is especially problematic with milder forms, where the fractures may be the only obvious sign and the classic blue sclerae or dental abnormalities have not yet appeared. Genetic testing can resolve the question definitively, but it is not always ordered early in the process. Pediatric radiologists and child protection teams are increasingly aware of this differential, but cases of misdiagnosis still occur, with devastating consequences for families.
Treatment and the Limits of Current Therapy
Bisphosphonates, drugs that slow bone breakdown, have been the mainstay of OI treatment for decades. They reliably increase bone mineral density in both children and adults with OI. However, whether that increased density actually translates into fewer fractures is surprisingly unclear. A Cochrane review found that while bisphosphonates boost bone density, the evidence that they consistently reduce fractures is limited. A meta-analysis of placebo-controlled trials reached a similar conclusion: the proportion of patients who experienced a fracture was not significantly reduced by bisphosphonate therapy, with a pooled relative risk of 0.83 that just missed statistical significance. When looking at overall fracture rates, there was a modest reduction, but this was heavily influenced by a single study and became non-significant when that outlier was removed.
This gap between density gains and fracture prevention may reflect the fact that OI bone is not just thin but structurally abnormal. Adding mineral to a poorly organized collagen scaffold may not improve strength the way it does in osteoporosis, where the collagen is normal but underbuilt. The distinction matters because it shapes expectations for patients and families.
Emerging Therapies Targeting Bone Strength
The most closely watched new treatment is setrusumab, an antibody that blocks sclerostin, a protein that normally puts the brakes on bone formation. In a phase 2b trial (the Asteroid study), adults with OI Types I, III, or IV received monthly infusions of setrusumab at various doses or placebo for 12 months. The highest dose produced a meaningful increase in estimated bone failure load, a measure of how much force the bone can withstand before breaking, of about 3.2 percent. Bone stiffness also improved at the two higher doses. The gains were similar across OI types, which is encouraging because it suggests the drug does not only help the mildest cases.
However, the trial did not show a significant difference in fracture rates between treatment and placebo groups, likely because it was too small and too short to detect fracture prevention. A phase 3 trial is planned to address that question. Two participants in the highest-dose group experienced serious adverse reactions, a reminder that boosting bone formation pharmacologically carries risks.
The Economic Weight of a Rare Disease
Living with OI is expensive. A large international survey of adults with OI found that two-thirds visited a hospital within a 12-month period, and one-third visited the emergency department. On average, adults had undergone nearly 12 surgeries by the time they completed the survey, and the mean number of diagnostic tests in a single year was eight. Most adults with OI were employed, but nearly a third of those with jobs reported missing workdays. Out-of-pocket spending averaged about €191 over a four-week period, with higher costs consistently linked to female sex, more severe disease, and recent fractures.
These figures capture only direct costs. Indirect costs from reduced earning capacity, informal caregiving, home modifications, and assistive devices add substantially to the economic burden. Because OI is a lifelong condition with no cure, these expenses accumulate over decades. For families in countries without robust health insurance, the financial strain compounds the physical and emotional toll of the disease.
Prenatal Detection and What It Can and Cannot Tell You
Severe forms of OI, particularly Type II, can sometimes be detected before birth through ultrasound, which may reveal shortened or bowed limbs, rib fractures, or an unusually soft skull. When ultrasound identifies short long bones in a fetus, exome sequencing can help pin down the diagnosis. In a retrospective study of fetuses referred for short long bones on ultrasound, OI accounted for about 18 percent of diagnosed cases, making it the second most common cause after achondroplasia.
Prenatal genetic testing is most useful when there is a known family history or when ultrasound findings are strongly suggestive. For milder forms like Type I, prenatal detection is often impossible because the skeletal abnormalities are too subtle to see on imaging. Many individuals with Type I are not diagnosed until childhood, after they present with unexplained fractures, and some are not diagnosed until adulthood. The delay is partly because mild OI does not always look dramatically different from a child who is simply unlucky with injuries, and family history may be attributed to clumsiness or coincidence rather than a genetic condition.